A detailed history of Northern Trust Corp transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 74,955 shares of SPRB stock, worth $38,976. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,955
Previous 96,688 22.48%
Holding current value
$38,976
Previous $283,000 79.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$0.7 - $5.49 $15,213 - $119,314
-21,733 Reduced 22.48%
74,955 $59,000
Q4 2023

Feb 13, 2024

BUY
$1.04 - $2.93 $49,944 - $140,710
48,024 Added 98.68%
96,688 $283,000
Q3 2023

Nov 13, 2023

SELL
$2.04 - $2.54 $17,203 - $21,419
-8,433 Reduced 14.77%
48,664 $109,000
Q2 2023

Aug 11, 2023

BUY
$1.92 - $2.6 $83,243 - $112,725
43,356 Added 315.52%
57,097 $122,000
Q1 2023

May 15, 2023

SELL
$1.15 - $3.17 $374 - $1,033
-326 Reduced 2.32%
13,741 $30,000
Q2 2022

Aug 12, 2022

SELL
$1.28 - $2.23 $72,473 - $126,262
-56,620 Reduced 80.1%
14,067 $24,000
Q1 2022

May 13, 2022

SELL
$1.85 - $4.59 $7,999 - $19,847
-4,324 Reduced 5.76%
70,687 $143,000
Q4 2021

Feb 08, 2022

BUY
$2.33 - $5.74 $794 - $1,957
341 Added 0.46%
75,011 $334,000
Q3 2021

Nov 15, 2021

SELL
$6.01 - $11.26 $19,195 - $35,964
-3,194 Reduced 4.1%
74,670 $449,000
Q2 2021

Aug 13, 2021

BUY
$10.12 - $17.46 $17,406 - $30,031
1,720 Added 2.26%
77,864 $873,000
Q1 2021

May 12, 2021

SELL
$14.8 - $25.79 $45,288 - $78,917
-3,060 Reduced 3.86%
76,144 $1.26 Million
Q4 2020

Feb 11, 2021

BUY
$15.38 - $32.42 $1.22 Million - $2.57 Million
79,204 New
79,204 $1.93 Million

Others Institutions Holding SPRB

About SPRUCE BIOSCIENCES, INC.


  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $12.3M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.